Suppr超能文献

腺苷代谢:癌症治疗的新兴概念。

Adenosine Metabolism: Emerging Concepts for Cancer Therapy.

机构信息

Department of Neurosurgery, Robert Wood Johnson & New Jersey Medical Schools, Rutgers University, Piscataway, NJ 08854, USA; Rutgers Brain Health Institute, Piscataway, NJ 08854, USA.

MediCity Research Laboratory, University of Turku, Tykistökatu 6A, Turku, 20520, Finland.

出版信息

Cancer Cell. 2019 Dec 9;36(6):582-596. doi: 10.1016/j.ccell.2019.10.007.

Abstract

Adenosine is a key metabolic and immune-checkpoint regulator implicated in the tumor escape from the host immune system. Major gaps in knowledge that impede the development of effective adenosine-based therapeutics include: (1) lack of consideration of redundant pathways controlling ATP and adenosine levels; (2) lack of distinction between receptor-dependent and -independent effects of adenosine, and (3) focus on extracellular adenosine without consideration of intracellular metabolism and compartmentalization. In light of current clinical trials, we provide an overview of adenosine metabolism and point out the need for a more careful evaluation of the entire purinome in emerging cancer therapies.

摘要

腺苷是一种关键的代谢和免疫检查点调节剂,参与肿瘤逃避宿主免疫系统。阻碍有效的基于腺苷的治疗药物发展的主要知识空白包括:(1)缺乏对控制 ATP 和腺苷水平的冗余途径的考虑;(2)缺乏对腺苷受体依赖性和非依赖性作用的区分;以及(3)关注细胞外腺苷,而不考虑细胞内代谢和区室化。鉴于当前的临床试验,我们对腺苷代谢进行了概述,并指出在新兴的癌症治疗中需要更仔细地评估整个嘌呤组。

相似文献

1
Adenosine Metabolism: Emerging Concepts for Cancer Therapy.
Cancer Cell. 2019 Dec 9;36(6):582-596. doi: 10.1016/j.ccell.2019.10.007.
2
ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain.
Pharmacol Rev. 2022 Jul;74(3):797-822. doi: 10.1124/pharmrev.121.000528.
3
Targeting adenosine in cancer immunotherapy: a review of recent progress.
Expert Rev Anticancer Ther. 2017 Jun;17(6):527-535. doi: 10.1080/14737140.2017.1316197. Epub 2017 Apr 27.
4
Targeting adenosine for cancer immunotherapy.
J Immunother Cancer. 2018 Jun 18;6(1):57. doi: 10.1186/s40425-018-0360-8.
6
P2 receptors in cancer progression and metastatic spreading.
Curr Opin Pharmacol. 2016 Aug;29:17-25. doi: 10.1016/j.coph.2016.05.001. Epub 2016 May 24.
7
The adenosine pathway in immuno-oncology.
Nat Rev Clin Oncol. 2020 Oct;17(10):611-629. doi: 10.1038/s41571-020-0382-2. Epub 2020 Jun 8.
8
ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):278-285. doi: 10.1016/j.bbcan.2018.04.001. Epub 2018 Apr 10.
10
Inhibition of the Adenosinergic Pathway in Cancer Rejuvenates Innate and Adaptive Immunity.
Int J Mol Sci. 2019 Nov 14;20(22):5698. doi: 10.3390/ijms20225698.

引用本文的文献

1
Adenosine Concentration Determination for Tumor Microenvironment Simulation.
Dose Response. 2025 Aug 25;23(3):15593258251371484. doi: 10.1177/15593258251371484. eCollection 2025 Jul-Sep.
3
Exploring adenosine analogs for chondrosarcoma therapy: and insights.
Mol Ther Nucleic Acids. 2025 Jul 23;36(3):102642. doi: 10.1016/j.omtn.2025.102642. eCollection 2025 Sep 9.
4
Ap4A in Cancer: A Multifaceted Regulator and Emerging Therapeutic Target.
Molecules. 2025 Jul 22;30(15):3056. doi: 10.3390/molecules30153056.
7
Insights from Clinical Trials on A Adenosine Receptor Antagonists for Cancer Treatment.
ACS Pharmacol Transl Sci. 2025 May 2;8(6):1498-1512. doi: 10.1021/acsptsci.5c00057. eCollection 2025 Jun 13.
8
State of the art indicators for imaging purinergic dynamics in vitro and in vivo.
Purinergic Signal. 2025 Jun 17. doi: 10.1007/s11302-025-10095-6.
9
Bioactive polydopamine nanomedicines-assisted cancer immunotherapy.
Mater Today Bio. 2025 May 13;32:101864. doi: 10.1016/j.mtbio.2025.101864. eCollection 2025 Jun.
10
Adenosine Kinase: An Epigenetic Modulator and Drug Target.
J Inherit Metab Dis. 2025 May;48(3):e70033. doi: 10.1002/jimd.70033.

本文引用的文献

1
An Exceptionally Potent Inhibitor of Human CD73.
Biochemistry. 2019 Aug 6;58(31):3331-3334. doi: 10.1021/acs.biochem.9b00448. Epub 2019 Jul 23.
2
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.
Front Immunol. 2019 Jun 6;10:925. doi: 10.3389/fimmu.2019.00925. eCollection 2019.
5
The role of NK cells and CD39 in the immunological control of tumor metastases.
Oncoimmunology. 2019 Apr 2;8(6):e1593809. doi: 10.1080/2162402X.2019.1593809. eCollection 2019.
6
Microvesicles expressing adenosinergic ectoenzymes and their potential role in modulating bone marrow infiltration by neuroblastoma cells.
Oncoimmunology. 2019 Feb 19;8(5):e1574198. doi: 10.1080/2162402X.2019.1574198. eCollection 2019.
7
Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy.
Front Immunol. 2019 Apr 5;10:698. doi: 10.3389/fimmu.2019.00698. eCollection 2019.
8
Shortage of Cellular ATP as a Cause of Diseases and Strategies to Enhance ATP.
Front Pharmacol. 2019 Feb 19;10:98. doi: 10.3389/fphar.2019.00098. eCollection 2019.
9
Purine Release, Metabolism, and Signaling in the Inflammatory Response.
Annu Rev Immunol. 2019 Apr 26;37:325-347. doi: 10.1146/annurev-immunol-051116-052406. Epub 2019 Jan 24.
10
CD73 (Cluster of Differentiation 73) and the Differences Between Mice and Humans.
Arterioscler Thromb Vasc Biol. 2019 Mar;39(3):339-348. doi: 10.1161/ATVBAHA.118.311579.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验